The roughly 350bp widening in the combined ratio since 2024Q3 is almost entirely a loss-ratio story (87.7% to 91.8%), while the expense ratio has held between 6.9% and 7.9%, suggesting administrative discipline has remained intact and that medical cost trend against largely fixed state rates is the pressure point. The 2025Q4 print is internally inconsistent — a 77.5% loss ratio alongside a 101.4% combined ratio and a 24.0% expense ratio — which may reflect reserve or allocation distortions rather than a genuine underwriting swing, and it coincided with claims reserves falling to $8.8 billion from $10.6 billion. Because the 2026Q2 combined ratio is unavailable and the 98.7% figure sitting in that quarter's expense-ratio column appears mislabeled, the recovery trajectory after 2025Q4 should be treated as tentative until verified.

Underwriting contributed roughly 1.0% in 2026Q3 versus 4.5% in 2024Q3, which appears to explain most of the ROE decline, with investment yield on float acting as a smaller offsetting factor that the supplied tables do not separately quantify. The 2025Q4 ROE of -3.9% and negative 3.12 interest coverage for that quarter suggest the loss was concentrated rather than structural, but three consecutive sub-1.5% quarters since imply the recovery has not yet reached the income statement. Given that operating cash flow was negative in seven of ten quarters despite positive net income in several, investors should consider that the reported ROE may flatter the true economic return to capital.

A 2.61x book multiple against a 0.9% quarterly ROE implies the market is capitalizing on a margin recovery that trailing quarters have not demonstrated, so the 39.86 forward multiple looks to embed a rebound investors should be able to see evidence of in the combined ratio. Because equity declined from roughly $4.8 billion to $4.2 billion alongside about $2 billion of buybacks, the P/B may be flattered partly by a shrinking denominator rather than by franchise re-rating, an effect worth adjusting for before reading the multiple as a quality premium. The trailing P/E of 23.45 against a forward of nearly 40 further suggests consensus expects current-period earnings to trough before recovering, a view that warrants confirmation against Medicaid rate filings.

With premium-to-surplus unavailable, the debt-to-equity trajectory serves as the nearest proxy for balance-sheet gearing, and its doubling over ten quarters appears driven at least as much by the denominator shrinking under share repurchases as by any accumulation of debt. That distinction matters for rating-agency headroom: a capital base that fell 12.5% while total assets ended near $15.7 billion suggests less absorptive capacity for adverse reserve development, even if absolute leverage remains moderate for the sector. Investors should look to disclosed policyholder surplus and regulatory capital ratios before concluding the underwriting leverage position is stable.

Molina's positive underwriting margin versus Centene's deeply negative returns appears consistent with the lean-specialist cost structure holding up better through the redetermination cycle, which may justify the relative premium even though absolute profitability has clearly deteriorated. The gap to Alignment Health, however, indicates the market applies a very different valuation framework to a higher-returning, smaller peer, so MOH's multiple seems to reflect a mid-cycle recovery trade rather than a quality compounding case. If Medicaid rate stabilization proves less durable than recent commentary implies, the premium to Centene would have little fundamental support beyond the current-quarter ROE differential.